Clinical Trials Logo

Macrophage Activation Syndrome clinical trials

View clinical trials related to Macrophage Activation Syndrome.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05137496 Not yet recruiting - Clinical trials for Macrophage Activation Syndrome

Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

Start date: June 1, 2022
Phase: Phase 3
Study type: Interventional

The present study was a single-center, prospective, non-comparative in which macrophage activation syndrome patients were selected as the main subjects to evaluate the effect and safety of Ruxolitinib and methylprednisolone regimens as the first-line therapy .

NCT ID: NCT03721809 Not yet recruiting - Clinical trials for Macrophage Activation Syndrome

Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis

SAMOKINE
Start date: November 2018
Phase: N/A
Study type: Interventional

The pathophysiology of macrophage activation syndrome has been mainly studied in pediatric genetic primary forms. There is little data in secondary forms related to bacterial sepsis. Because of the seriousness of this entity (43% of deaths in intensive care in the largest cohort published so far by the medical resuscitation team of Rouen University Hospital), it is necessary to better understand the physiopathological mechanisms to be able to propose a suitable therapy. For now, the management of this syndrome is far from consensual. Some authors advocate a single etiological treatment, while others suggest the need for intensive management of anti-inflammatory and immunosuppressive type. The fragility of resuscitation patients does not allow intensive immunosuppressive therapies as proposed by some authors. In the era of immunotherapy, the precise knowledge of physiopathological data would make it possible to propose a targeted therapy with little risk of adverse effects. Recent work has indeed shown excellent tolerance of immunotherapy during sepsis and could be applied eventually in patients with macrophage activation syndrome.